ENSC
Ensysce Biosciences, Inc.
ENSC lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ENSC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
ENSC's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ENSC PE Valuation
ENSC has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ENSC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect ENSC's losses to shrink, with revenue growing.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ENSC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.75 | +$8.47 |
| Q2 2026 | -$2.52 | +$9.36 |
| Q1 2026 | -$3.11 | +$11.28 |
| Q4 2025 | -$3.98 | +$17.27 |
| Q3 2025 | -$14.22 | +$7.68 |
| Q2 2025 | -$11.88 | +$24.12 |
| Q1 2025 | -$14.39 | +$33.01 |
| Q4 2024 | -$21.25 | +$49.10 |
ENSC has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ENSC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.2M | +342% |
| Q2 2026 | $1.2M | -15% |
| Q1 2026 | $961K | -27% |
| Q4 2025 | $1.9M | +44% |
| Q3 2025 | $493.1K | -86% |
| Q2 2025 | $1.4M | +654% |
| Q1 2025 | $1.3M | +332% |
| Q4 2024 | $1.3M | +153% |
ENSC's revenue is recovering but still below its 2024 peak: $2M last quarter, up 342% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3781% | -3023 points |
| Q2 2026 | -221% | -94 points |
| Q1 2026 | -371% | -222 points |
| Q4 2025 | -148% | +127 points |
| Q3 2025 | -759% | -778 points |
| Q2 2025 | -128% | +948 points |
| Q1 2025 | -149% | +454 points |
| Q4 2024 | -274% | +338 points |
ENSC's operating margin was −3781% last quarter, down 3023 points from the same quarter a year ago, near the bottom of its range since 2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ENSC on profitability, with a higher operating margin.
ENSC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | +$744.4K |
| Q1 2026 | -$3.5M | -$1.8M |
| Q4 2025 | -$1.5M | -$761.7K |
| Q2 2025 | -$2.7M | -$397K |
| Q1 2025 | -$1.7M | +$1.7M |
| Q4 2024 | -$764.1K | +$1M |
| Q3 2024 | -$1M | +$1.2M |
| Q2 2024 | -$2.3M | +$798.7K |
ENSC has the stronger cash trend. Its trailing FCF is up 6.3% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ENSC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +40% | +5.2M shares |
| 1 year | +530% | +15.3M shares |
| 3 years | +25787% | +18.1M shares |
| 5 years | +985979% | +18.2M shares |
| Available history | +1077056% | +18.2M shares |
ENSC has 18M diluted shares, up 530% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | $136.3M |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ENSC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ENSC Net Leverage
ENSC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ENSC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 20.9 | Neutral |
ENSC's weekly RSI is 45 (neutral) and its Stochastic is 21 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ENSC PE vs Healthcare Sector
| Metric | ENSC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ENSC has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ENSC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.43 | 9.3% below |
| 20 week MA | $0.40 | 2.5% below |
| 50 week MA | $0.53 | 26% below |
| 100 week MA | $1.97 | 80% below |
| 200 week MA | $14.8 | 97% below |
ENSC is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ENSC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37,224.0 | $47,808.0 | +28% |
| 2021 | $47,808.0 | $18,432.0 | -61% |
| 2022 | $18,432.0 | $129.6 | -99% |
| 2023 | $129.6 | $15.9 | -88% |
| 2024 | $15.9 | $8.88 | -44% |
| 2025 | $8.88 | $1.10 | -88% |
| 2026 YTD | $1.10 | $0.39 | -65% |
ENSC has finished five years in a row lower, and it's down 65% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ENSC on returns for 2026, with the stronger performance.